A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cyclerion Therapeutics
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subject is an ambulatory adult and between 18 and 55 years old (inclusive) at the screening visit
Subject is in good health and has no clinically significant findings on physical examination
Body mass index is \> 18 and \< 30 kg/m2 at the screening visit
Women of reproductive potential must have a negative pregnancy test at screening at at the time of check-in and must agree to use protocol-specified contraception throughout the duration of the study and until 90 days after receiving the final study drug dose
Men must agree to use protocol-specified contraception and also to not donate sperm throughout the study and until 90 days after receiving the final study drug dose
You may not be if
Any active or unstable clinically significant medical condition
Use of any prescribed or non-prescribed medication (except for hormonal birth control)
Clareo Health | A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers
